Navigation Links
New Long-Term Study Suggests Lower Mortality in Alzheimer's Patients Treated with Galantamine Versus Placebo
Date:12/5/2012

s sold as RAZADYNE® and RAZADYNE® ER by Janssen Pharmaceuticals, Inc.

Important Safety Information

In clinical trials, once-daily treatment with RAZADYNE® ER was well tolerated and the adverse events were similar to those seen with twice daily RAZADYNE® tablets.

Anesthesia

Cholinesterase inhibitors, such as galantamine HBr, are likely to exaggerate the neuromuscular blocking effects of succinylcholine-type and similar neuromuscular blocking agents during anesthesia.

Cardiovascular events

Because of their pharmacologic action, cholinesterase inhibitors have vagotonic effects on the sinoatrial (SA) and atrioventrical (AV) nodes, leading to bradycardia and AV block. These actions may be particularly important to patients with superventricular cardiac conduction disorders, or to patients taking other drugs concomitantly that significantly slow heart rate. In clinical trials, galantamine HBr was associated with more frequent reports of bradycardia and syncope vs placebo. Post marketed surveillance of marketed anticholinesterase inhibitors has shown that bradycardia and all types of heart block have been reported in patients both with and without known underlying cardiac conduction abnormalities. All patients should be considered at risk for adverse effects on cardiac conduction.

Gastrointestinal

Cholinesterase inhibitors may increase gastric acid secretion. Patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk of developing ulcers, eg, those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs.

Genitourinary

Cholinesterase inhibitors may cause bladder outflow obstruction.

Neurological conditions

Cholinesterase inhibitors are believed to have some potential to cause generalized convulsions. Seizure
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
2. Rituximab Promotes Long-Term Response for Patients with Immune Destruction of Platelets
3. New Study Shows Long-Term Effects of Drug Prevention
4. Ceregene Parkinsons Disease Study Demonstrates Long-term Neurturin Expression and Enhanced Dopamine Activity 4 Years Following Delivery of CERE-120 (AAV2-neurturin)
5. Unilife Signs Long-Term Supply Contract for the Unifill Prefilled Syringe
6. Vocollect Healthcare Systems And Prime Care Technologies Bring AccuNurse Key Performance Metrics To Long-Term Care Providers Via primeVIEW Digital Dashboard
7. GlaxoSmithKline Employees Embark on Long-Term Volunteer Assignments throughout the World
8. Savient Pharmaceuticals Announces CEO Appointment and Reorganization Plan to Drive Long-Term Growth
9. Long-Term Use of Blood Pressure Medications that Promote Sun Sensitivity May Increase Risk of Lip Cancer in Non-Hispanic Whites
10. Pfizer and Mylan Team Up to Establish Exclusive Long-Term Strategic Collaboration to Drive Sustained Growth of Generics Business in Japan
11. Greenphires ClinCard Technology Platform selected by top 5 pharmaceutical company for long-term global clinical trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 4, 2015 UPM Pharmaceuticals, a division of ... Sprout Pharmaceuticals to manufacture Flibanserin 100 mg tablets. Sprout ... the first drug approved to treat hypoactive sexual desire ... dysfunction. The tablets will be manufactured at ... Tennessee . Dr. John M. ...
(Date:3/4/2015)... 4, 2015 Following the reintroduction of ... Center (LAC) released a report today urging policymakers ... and heroin epidemic through more effective use of ... "The Case for Expanding Access to Medication-Assisted Treatment ... the health, justice, and economic advantages of medication-assisted ...
(Date:3/4/2015)... 2015  Heska Corporation (Nasdaq: HSKA ) ... Join Its Fourth Quarter and Year End 2014 Earnings ... 9:00 a.m. (MST) / 11:00 a.m. (EST)Where: www.heska.com ... Call link on the front page of this website)How:Live ... web at the address above.  Alternatively, you may use ...
Breaking Medicine Technology:UPM Pharmaceuticals to Manufacture Sprout Pharmaceuticals' Flibanserin Tablets 2UPM Pharmaceuticals to Manufacture Sprout Pharmaceuticals' Flibanserin Tablets 3Improved Medication-Assisted Treatment Policy Could Aid Epidemic of 20 Million Americans with Untreated Addiction 2Webcast Alert: Heska Announces Fourth Quarter and Year End 2014 Earnings Conference Call Webcast 2
... , MELVILLE, N.Y. , Jan. 25 ... provider of health care products and services to office-based practitioners, announced today ... and Chief Financial Officer, will present at the Jefferies 2010 Global Healthcare ... Schein,s presentation is scheduled to begin at 3:30 p.m. EST ...
... , , RYE, N.Y. , ... a drug research and development company focused on the treatment of neurological ... clinical trials for CM-AT, its autism treatment, at ten sites across the ... New York City Drexel University , Philadelphia ...
Cached Medicine Technology:Henry Schein To Present At The Jefferies 2010 Global Healthcare Services Conference 2Curemark Enrolling Patients In Phase III Autism Trials At Ten Sites 2Curemark Enrolling Patients In Phase III Autism Trials At Ten Sites 3Curemark Enrolling Patients In Phase III Autism Trials At Ten Sites 4
(Date:3/4/2015)... Vancouver chiropractic clinic, Backs in Action ... the prestigious Vancouver Courier “Stars of Vancouver” 2015 ... company secured third place in the “Best Chiropractor” ... Massage Therapist” category. , As one of ... Vancouver Courier is a semiweekly local newspaper published ...
(Date:3/4/2015)... 04, 2015 " Optrix by Body ... its monthly Tech Report, which takes a look at ... to consumers. Scott Steinberg, a special reporter for NewsWatch ... shared with viewers how they have an ultra-rugged, waterproof ... industry is a major player at the Consumer Electronics ...
(Date:3/4/2015)... March 04, 2015 The Global ... billion in 2014 and is estimated to grow ... of 4.0% from 2014 to 2019. , Browse ... Market for an analysis of industry trends, segments ... global liquefied petroleum gas market is classified into ...
(Date:3/4/2015)... Organic Valley, the nation’s largest cooperative of ... cause campaign to Save the Bros, http://savethebros.com/ with ... difference to Bros everywhere. To date, the video has ... The video was named Adweek’s best commercial of the week ... Digiday, among other media outlets. , “We are pleased ...
(Date:3/4/2015)... Columbus is no stranger to drug addiction. The ... addiction, and suffers from the potential threat of Kratom. In ... DEA revealed that Kratom is a “drug of concern.” Although ... introduced herb from Southeast Asia acts as a stimulant in ... kratom foments symptoms similar to heroin withdrawal, and includes tremors, ...
Breaking Medicine News(10 mins):Health News:Backs in Action Receives Two Awards in The Vancouver Courier Readers’ Choice Awards 2015 2Health News:A Waterproof Phone Case with an Interchangeable Lens System was Featured on NewsWatch Television on January 30, 2015 2Health News:The Global Liquefied Petroleum Gas Market is Estimated to Reach $288.7 Billion by 2019 - A Report by MicroMarket Monitor 2Health News:The Global Liquefied Petroleum Gas Market is Estimated to Reach $288.7 Billion by 2019 - A Report by MicroMarket Monitor 3Health News:ORGANIC VALLEY URGES PUBLIC TO SAVE THE BROs: CAMPAIGN EARNS MORE THAN 1M VIEWS ON YOUTUBE 2Health News:ORGANIC VALLEY URGES PUBLIC TO SAVE THE BROs: CAMPAIGN EARNS MORE THAN 1M VIEWS ON YOUTUBE 3Health News:Columbus, OH Combats the Sale of Kratom as a Drug, Harbor Village Detox Stresses Caution 2
... , , IRVINE, Calif., Aug. ... share of $0.49 for the quarter ended June 30, 2009, a 24% ... The Company reported quarterly revenues of $81 million, a 4% increase compared ... , The Company,s results are reflective of improved growth ...
... an increased risk of death, found a new study of ... in CMAJ ( Canadian Medical Association Journal ) ... approximately 25% of people (both men and women) living in ... develop a spine fracture will die over a 5 year ...
... ... their already booming empire of top physicians. The much awaited International Association of Dermatologists ... their renowned directory, "The Leading Physicians Of the World". , ... New York, NY (PRWEB) August 3, 2009 ...
... , , CHICAGO, Aug. 3 Eczema ... rashes. It is commonly known as "the itch that rashes." (1) ... appears to result from a complex interaction of factors including personal and ... Scratching the affected area can lead to more itch, redness, swelling, ...
... Commentary by Betsy McCaughey ,rife with gross, cruel distortions, ... York State Director Lois Aronstein issued the following statement in response to ... reform measures passed or currently being considered by Congress. , , ... various media outlets is rife with gross -- and even cruel -- ...
... , , , ... N.C., Aug. 3 Kowa Research Institute (KRI) based in ... specialty pharmaceutical company headquartered in Montgomery, AL, announced today that ... (R) (pitavastatin), a potent HMG-CoA reductase inhibitor (statin), for ...
Cached Medicine News:Health News:CorVel Announces Revenues and Earnings 2Health News:CorVel Announces Revenues and Earnings 3Health News:CorVel Announces Revenues and Earnings 4Health News:CorVel Announces Revenues and Earnings 5Health News:Hip and back fractures increase mortality rates in people older than 50 2Health News:Top Dermatologists to be Selected and Published in "The Leading Physicians of the World" Consumer Directory. 2Health News:Five Questions About Eczema 2Health News:Five Questions About Eczema 3Health News:Five Questions About Eczema 4Health News:Five Questions About Eczema 5Health News:AARP Responds to Health Reform Scare Tactics 2Health News:AARP Responds to Health Reform Scare Tactics 3Health News:FDA Approves LIVALO(R) for Primary Hypercholesterolemia and Combined Dyslipidemia 2Health News:FDA Approves LIVALO(R) for Primary Hypercholesterolemia and Combined Dyslipidemia 3Health News:FDA Approves LIVALO(R) for Primary Hypercholesterolemia and Combined Dyslipidemia 4
The Medtronic EOPA CAP® arterial cannula provides a simple solution to obtaining accurate arterial pressure readings....
Intermittent catheter...
Intermittent catheter...
... new dimension in vitreoretinal surgery. ,By ... of purified perfluoro-n-octane, you can greatly ... ideal for managing retinal detachments complicated ... and trauma. , ,Certified to be ...
Medicine Products: